厄贝沙坦联合美托洛尔治疗慢性充血性心衰的疗效观察

　　摘   要：目的  观察厄贝沙坦联合美托洛尔治疗慢性充血性心衰的临床疗效。方法  选择我院自2015年3月～2016年5月收治68例慢性充血性心衰患者作为研究对象，将其随机分成对照组和研究组，每组34例。对照组采用厄贝沙坦治疗，研究组采用厄贝沙坦联合美托洛尔治疗，比较两组患者治疗前后的心率（HR）、收缩压（SBP）和舒张压（DBP）等血压水平以及左室舒张末内径（LVEDd）、左室收缩末内径（LVESd）和左室射血分数（LVEF）等左心功能指标，并统计和计算两组患者治疗期间的不良反应发生率及治疗的总有效率。结果  两组患者治疗前的心率、血压及各项左心功能水平对比，差异均无统计学意义（P>0.05）。治疗期间，研究组与对照组的不良反应发生率对比差异统计学意义（P>0.05）。治疗后，研究组的HR、DBP、DBP、LVEDd、LVESd均明显低于对照组，研究组的LVEF、治疗的总有效率明显高于对照组，两组对比差异有统计学意义（P<0.05）。结论  对慢性充血性心衰患者采用厄贝沙坦联合美托洛尔治疗，不仅能有效改善患者的心率和血压水平，同时还能有效促進患者的左心功能恢复，患者治疗期间的毒副反应发生率较低，因此其是一组安全、高效的组合治疗药物。
　　关键词：厄贝沙坦;美托洛尔;慢性充血性心衰
　　中图分类号：R541.6                                  文献标识码：A                                DOI：10.3969/j.issn.1006-1959.2018.05.044
　　文章编号：1006-1959（2018）05-0125-03
　　Efficacy of Irbesartan Combined with Metoprolol in the Treatment of Chronic Congestive Heart Failure
　　ZHANG Ting
　　（Department of Dry Diagnosis，157 Hospital，Shenyang 110045，Liaoning，China）
　　Abstract：Objective  To observe the clinical efficacy of irbesartan combined with metoprolol in the treatment of chronic congestive heart failure.Methods  68 patients with chronic congestive heart failure from March 2015 to May 2016 were randomly divided into control group（n=34）and study group（n=34）.The control group was treated with irbesartan and the study group with irbesartan combined with metoprolol.Before and after treatment，the blood pressure levels，such as heart rate（HR），systolic blood pressure（SBP）and diastolic blood pressure（DBP），left ventricular end-diastolic diameter（LVEDd），left ventricular end-systolic diameter （LVESd）and left ventricular ejection fraction（LVEF）were compared between the two groups.The incidence of adverse reactions during treatment and the total effective rate of treatment were counted and calculated.Results  There was no significant difference in heart rate，blood pressure and left ventricular function between the two groups before treatment（P>0.05）.During the treatment period，the incidence of adverse reactions in the study group and the control group was significantly different（P>0.05）.After treatment，the HR，DBP，DBP，LVEDd and LVESd in the study group were significantly lower than those in the control group.The total effective rate of LVEF and treatment in the study group was significantly higher than that in the control group，the difference between the two groups was statistically significant（P<0.05）.Conclusion  Irbesartan combined with metoprolol in patients with chronic congestive heart failure can not only improve the heart rate and blood pressure，but also promote the recovery of left ventricular function.The incidence of side effects during treatment is low，so it is a safe and effective combination of drugs.

相关热词搜索：心衰 疗效 洛尔 观察 治疗慢性